Head to Head Contrast: Organon & Co. (NYSE:OGN) vs. Ardent Health (NYSE:ARDT)

Ardent Health (NYSE:ARDT) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Institutional and Insider Ownership

77.4% of Organon & Co. shares are held by institutional investors. 1.7% of Ardent Health shares are held by insiders. Comparatively, 2.0% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Ardent Health and Organon & Co.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ardent Health	3.24%	19.02%	6.04%
Organon & Co.	7.95%	143.47%	7.14%

Earnings and Valuation

This table compares Ardent Health and Organon & Co.”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardent Health	$5.97 billion	0.21	$210.34 million	$1.45	6.10
Organon & Co.	$6.40 billion	0.33	$864.00 million	$1.92	4.18

Organon & Co. has higher revenue and earnings than Ardent Health. Organon & Co. is trading at a lower price-to-earnings ratio than Ardent Health, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ardent Health has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Ardent Health and Organon & Co., as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardent Health	2	4	6	0	2.33
Organon & Co.	4	2	0	1	1.71

Ardent Health presently has a consensus target price of $14.67, suggesting a potential upside of 65.82%. Organon & Co. has a consensus target price of $8.38, suggesting a potential upside of 4.36%. Given Ardent Health’s stronger consensus rating and higher probable upside, equities analysts clearly believe Ardent Health is more favorable than Organon & Co..

Summary

Organon & Co. beats Ardent Health on 10 of the 15 factors compared between the two stocks.

About Ardent Health

Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.